2.94
-2.65%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biofrontera
Its shares trade on XETRA under the ticker B8FK.DE. It has been listed since 30 October 2006. In the fiscal year to 31 December 2025, it reported revenue of €13.2m and a net loss of €4.0m. At that date it held total assets of €20.6m and shareholders' equity of €14.9m.
Biofrontera AG operates as a biopharmaceutical company, which engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. The company is headquartered in Leverkusen, Nordrhein-Westfalen. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Oct 2006
- Employees
- 155
- Website
- biofrontera.com ↗
Leadership
Pay as last reported
- Mr. Alexander LinkChairman of the Supervisory Board, since 2024€15,000
- Dr. Helge LubenowVice Chairman of the Supervisory Board, since 2021€34,000
- Ms. Pilar De La Huerta MartinezChief Financial Officer, Member of the Management Board€425,000
- Dr. Heikki LanckrietMember of the Supervisory Board€22,000
- Mr. Hansjoerg PlaggemarsMember of the Supervisory Board€9,000
- Mr. Tobias ReichMember of the Supervisory Board€8,000
- Mr. Karlheinz SchmeligMember of the Supervisory Board€28,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biofrontera AG develops Ameluz for photodynamic therapy of actinic keratoses in Germany.
- The company's PDT lamp BF-RhodoLED supports Ameluz treatment for skin cancer patients.
- Belixos cream treats itching and inflamed skin conditions like psoriasis in Europe.
Weaknesses
- Biofrontera AG has only 155 employees in the Health Care sector.
- The firm's clinical development of BF-derm1 is still in progress for allergies.
- BF1 drug candidate is under development for migraine prevention in Germany.
Opportunities
- Biofrontera AG can expand Ameluz use for other skin cancer types in Europe.
- The company may develop BF-derm1 for allergic reaction treatment in the Health Care sector.
- Belixos cream could target new markets for skin inflammation in Germany.
Threats
- Biofrontera AG faces competition from other dermatological drug developers in Germany.
- The clinical development of BF-derm1 might face delays in the Health Care industry.
- BF1 drug candidate could encounter regulatory hurdles in the European market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.